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Identiﬁes New Human
Collagen Genes Involved
in Cardiac RemodelingVentricular remodeling, a process involving mor-
phological changes in cardiomyocytes and the extra-
cellular matrix (ECM), has been linked to worsening
of clinical status and heart failure (HF) development.
In HF, remodeling initially occurs as a compensatory
response to preserve the structural integrity of the
myocardium, but progressive collagen deposition can
lead to cardiac ﬁbrosis and impairment of diastolic
and systolic function (1). Thus, we analyzed changesin the expression proﬁle of collagen-related genes in
patients with ischemic cardiomyopathy (ICM) and
examined the relationships with left ventricular (LV)
dysfunction.
We obtained 23 human LV tissue samples from
patients with ICM (13 men; mean age, 54  8 years)
with end-stage HF undergoing heart transplantation
and control donors (CNT) (8 men, 2 women; mean
age, 47  16 years). All control donors had normal LV
function (ejection fraction >50%) and no history of
cardiac disease. As an established condition for in-
clusion in the study, all selected samples displayed a
260/280 nm absorbance ratio >2.0 and RNA integrity
number $9. Transcriptome-level differences between
ICM and CNT samples were investigated by means
of large-scale screening of 23 heart samples with
the use of RNA-sequencing technology and fur-
ther validated by means of real-time (RT-PCR)
and Western blot analysis (Figure 1). These data
have been deposited in the NCBI Gene Expression
Omnibus (GEO) (retrieved by use of the GEO Series
accession No. GSE55296). We performed quantitative
RT-PCR assays in duplicate with the use of TaqMan
technology in the ViiA7 The Fast Real-Time RT-PCR
System (Applied Biosystems, Foster City, California);
collagen IV (COL4A5, Hs00166712_m1), collagen XIV
(COL14A1, Hs00964045_m1), and collagen XVI
(COL16A1, Hs00156876_m1) was obtained from Taq-
Man. Housekeeping genes GAPDH (Hs99999905_m1),
PGK1 (Hs99999906_m1), and TFRC (Hs00951083_m1)
were used as reference. Regarding the Western blot
analysis, tissue samples were transferred into Lysing
Matrix D tubes designed for use with the FastPrep-24
homogenizer (MP Biomedicals, Santa Ana, California).
Protein samples were separated by tris-acetate elec-
trophoresis on 3% to 8% polyacrylamide gels under
no-reducing conditions and transferred to a PVDF
membrane with the use of the iBlot Gel Transfer
Device (Life Technologies, Carlsbad, California) for
Western blot analyses. The primary detection an-
tibodies used were anti-COL4A5 rabbit polyclonal
(sc-11360) obtained from Santa Cruz Biotechnology,
anti-COL14A1 rabbit polyclonal (ab-101464) obtained
from Abcam, and anti-COL16A1 rabbit polyclonal
(A-96190) obtained from Sigma; monoclonal anti-
GAPDH antibody (ab-9484) from Abcam was used as
a loading control. We must note that patients with
end-stage HF are under heavy medical treatment,
and some therapies might inﬂuence mRNA levels.
We compared ICM and CNT samples, and we found
signiﬁcantly increased mRNA levels of 11 collagen
genes, such as COL9A1, COL11A2, COL14A1, and
COL16A1 (p < 0.05 for all), not previously described in
the cardiac remodeling process. A heat map and
FIGURE 1 Effects of Heart Failure on Collagen Gene Expression Levels
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(A) Hierarchical clustering shows the separation of both ischemic cardiomyopathy (ICM)
and control donor (CNT) groups. (B) The differential expression of COL4A5, COL14A1, and
COL16A1 was validated by means of quantitative RT-PCR and Western (W) blot, respec-
tively, in ischemic heart (salmon bars) versus control (fold change). Results were
considered statistically signiﬁcant at *p < 0.05, **p < 0.01, versus CNT. Bars represent
mean  SEM values.
Letters J A C C V O L . 6 5 , N O . 1 2 , 2 0 1 5
M A R C H 3 1 , 2 0 1 5 : 1 2 6 3 – 7 1
1266hierarchical clustering analysis identiﬁed 2 divergent
gene expression proﬁles, showing a clear separation
of the ICM and CNT groups (Figure 1). We also found
signiﬁcant relationships between LV dysfunction
and the gene expression levels of COL4A5 (fractional
shortening, r¼0.694, p<0.05) andCOL16A1 (LV end-
systolic diameter and LV end-diastolic diameter, r ¼
0.678, p < 0.05, and r ¼ 0.687, p < 0.05, respectively).
For validation of the novel regulated transcripts,
we performed quantitative RT-PCR and Western blotanalysis, focusing on those related signiﬁcantly with
the LV function: COL16A1 and COL4A5, and COL14A1,
newly described. These results (Figure 1) conﬁrm that
patients with ICM showed direction changes in
expression identical to what we found in the RNA-Seq
analysis.
Collagens types IX, XIV, and XVI belong to the ﬁbril-
associated collagens with interrupted triple helices
class, highly expressed in tissues that have high me-
chanical stress, such as heart tissue. Collagen IX is
thought to be required for several processes, including
eye and heart development, and its overexpression
has been observed in pathologies such as pectus exca-
vatum (2). In light of these studies, our results suggest
that overexpression of COL9A1 could lead to increased
cardiac tissue stiffness and may be potentially in-
volved in human heart development and remodeling.
Previous studies suggest that collagen XIV is
required to establish and maintain an organized ECM
environment in the developing myocardium and
plays an important role in regulating cardiomyocyte
growth and cardiac ﬁbroblast survival (3). During
replacement ﬁbrosis, cardiomyocytes undergo hy-
pertrophic adaptive changes, whereas myoﬁbroblasts
remain at the site of injury; this results in collagen
deposition and scar formation. We propose that
collagen XIV expression could promote this process.
Collagen XVI, a minor collagen component of
connective tissues, is thought to act as a linker pro-
tein, helping to organize the large ﬁbrillar networks
that modulate ECM integrity and stability. A recent
study proposed that in Crohn’s disease, increased
collagen XVI expression would promote formation
and maturation of focal adhesion contacts on intes-
tinal subepithelial myoﬁbroblasts (4). This would
retain the cells at the inﬂammation site, promoting
ﬁbrotic responses in the tissue and prolonging dis-
turbances of cellular and ECM homeostasis. We sug-
gest that dysregulated collagen XVI expression could
play a similar role in cardiac tissue by keeping myo-
ﬁbroblasts at the inﬂammation site and promoting
pathological remodeling.
Furthermore, collagen XI promotes the nucleation
of type I and II ﬁbrils and is required for myocardial
morphogenesis (5). The overexpression of COL11A2
may be related to the formation of heterotypic ﬁbrils
with collagen I, involved in cardiac remodeling.
Our ﬁndings propose that these collagen genes
may have novel roles in the remodeling process,
regulating the size increase of cardiomyocytes and
the survival of myoﬁbroblasts at the inﬂammation
site and assisting the organization in ﬁbers of other
collagens, such as type I and III. All these processes
jointly may facilitate the development of cardiac
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1267ﬁbrosis and, consequently, ventricular dysfunction.
Inhibition of collagen remodeling can lead to im-
proved cardiac function, demonstrating the relevance
of new insights into the compensatory remodeling
mechanism. Thus, our ﬁndings give new theoretical
support for the treatment of patients with ischemic
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Unsaturated Fatty Acids
and Arrhythmia Risk
Inﬂuences of Load Conditions and a
Differential Endogenous MetabolismWe read with great interest the recent report by
Nigam et al. (1) about the AFFORD (Multi-CenterStudy to Evaluate the Effect of n-3 Fatty Acids
[Omega-3] on Arrhythmia Recurrence in Atrial
Fibrillation) trial. Supplementation of 4 capsules ﬁsh
oil per day (containing a total of 1,600 mg eicosa-
pentaenoic acid, 20:5n-3, and 800 mg docosahexae-
noic acid [DHA], 22:6n-3) was shown not to reduce
recurrence of atrial ﬁbrillation. In parallel, markers of
inﬂammation or oxidative stress were not affected.
Up to now, numerous studies have provided a large
variety of potential effects attributed to highly un-
saturated fatty acid (HUFA) treatment ranging from
marked prognostic improvements in heart failure and
antiarrhythmogenic actions to no incremental effects.
Due to the divergent results, the question arises
whether mechanisms exist beyond an external HUFA
intake.
In heart failure, an inverse shift of serum fatty
acids occurs; particularly saturated and mono-
unsaturated fatty acids were increased, whereas
poly- and highly unsaturated omega-6 and omega-3
fatty acids were decreased (2,3). We have recently
shown that increased ventricular wall stress is
associated with reduced DHA levels (unpublished
data, P. Alter, January, 2015). Similar, but less
pronounced effects were found for eicosapentae-
noic acid and arachidonic acid (20:4n-6). Because
the liver is the major source of endogenous
HUFA, pseudocholinesterase activity, a marker of
hepatic metabolizing capacity, was examined
and shown to be inversely correlated with in-
creased end-diastolic and end-systolic ventricular
wall stress, which emphasizes the hypothesis of
a cardio-hepatic syndrome (e.g., inﬂuenced by
congestion). In addition, local variances of the
endogenous HUFA metabolism leading to in-
homogeneities of HUFA concentrations and effects
should be considered.
It was previously shown that systemic HUFA
levels in red blood cells and plasma correlate with
right atrial concentrations. Oral HUFA supplemen-
tation was incorporated into the atrial myocardium
(4). However, little is known about cardiac in-
ﬂuences on myocardial HUFA levels (5). We recently
found signiﬁcant differences of DHA concentrations
among atrial and ventricular myocardium in exper-
imental animals by using gas chromatography/mass
spectrometry (atrium 4.69  1.02% vs. ventricle
8.99  2.05%; p < 0.001) (unpublished, P. Alter,
January, 2015). It is suggested that different load
conditions, in particular increased wall stress, are
involved. Because DHA exhibits antiarrhythmogenic
actions, the question arises whether reduced
atrial DHA levels account for an increased risk of
atrial ﬁbrillation. Of note, intermediate DHA
